Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.39 |
| ▸ | CLPP | Q16740 | 2/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.38 |
| ▸ | TCF7 | P36402 | 2/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | TCF4 | P15884 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14319212 | 0.91 | CLPP (0.47) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL13774015 | 0.86 | CLPP (0.47) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL14504380 | 0.86 | CLPP (0.39) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL14309349 | 0.85 | CLPP (0.47) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL13773676 | 0.84 | CLPP (0.47) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL14319320 | 0.84 | CLPP (0.55) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL14309371 | 0.84 | CLPP (0.47) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL13773785 | 0.83 | CLPP (0.49) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL14309831 | 0.83 | CLPP (0.54) | CYP3A4CLPPCTNNB1TCF7BCL9 | |
| SCHEMBL14310059 | 0.83 | CLPP (0.48) | CYP3A4CLPPCTNNB1TCF7BCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | CYP3A4 1385/4885CLPP 4872/4885CTNNB1 1791/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | CYP3A4 1580/4885CLPP 4874/4885CTNNB1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.